Bosaeed 2022.
Study characteristics | |
Methods | Double‐blinded RCT |
Participants | Outpatients with confirmed COVID‐19 (mild‐ambulatory) treated in 7 centres in Saudi Arabia |
Interventions | Favipiravir, placebo |
Outcomes | Time from start of treatment to viral clearance, defined as the conversion of SARS‐CoV‐2 RT‐PCR from positive to negative within 15 days; symptom resolution; hospitalization; intensive care unit admissions; adverse events; and 28‐day mortality |
Notes |